{
  "submitter" : "Reach",
  "model_relation" : "extension",
  "extracted_information" : {
    "interaction_type" : "increases_activity",
    "negative_information" : true,
    "participant_b" : {
      "in_model" : true,
      "identifier" : "pubchem:23937",
      "entity_text" : "OS",
      "entity_type" : "simple_chemical"
    },
    "participant_a" : {
      "in_model" : true,
      "identifier" : "uaz:UAZ00174",
      "entity_text" : "rituximab",
      "entity_type" : "protein"
    },
    "hypothesis_information" : true
  },
  "verbose_text" : "[XREF_BIBR] In this study, we also found that rituximab combined with CHOP could not increase the OS or PFS in Chinese patients with DLBCL, which suggests that the combination of rituximab and CHOP cannot improve the curative rates for patients with DLBCL in China.",
  "reading_complete" : "2020-07-28T13:27:05Z",
  "reader_type" : "machine",
  "reading_started" : "2020-07-28T13:25:38Z",
  "trigger" : "increase",
  "evidence" : [ "rituximab combined with CHOP could not increase the OS" ],
  "pmc_id" : "5690734",
  "score" : 0
}